Idorsia Ltd (19T.SG)
| Previous close | 19.80 |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
GlobeNewswireNew data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5–8, 2024. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US, with availability planned for Q4 202
- GlobeNewswire
Amended terms of Idorsia’s 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the amended terms of Idorsia’s outstanding convertible bonds, originally maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds) have become effective. The cut-off date in respect of the consent fee is today, which means that bondholders holding the Bonds on – or who have purchased the
- GlobeNewswire
Idorsia announces financial results for the first half 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights Viatris collaboration: Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod.Adapted governance: On June 13, 2024, Jean-Paul Clozel retired from his position as CEO of Idorsia and was elected as Chairman. André C
